Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CRL

Earnings Preview: What To Expect From Charles River Laboratories' Report

Charles River Laboratories is scheduled to announce its first-quarter results next week, with analysts anticipating a single-digit earnings dip.

Barchart

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?

MarketBeat

How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks?

As Charles River Laboratories has underperformed its industry peers recently, analysts remain cautious about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Barchart

Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know

Charles River Laboratories will release its fourth-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector?

Charles River Laboratories has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Charles River Stock Will Climb or Sink?

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Charles River Laboratories' Q3 2024 Earnings: What to Expect

Charles River Laboratories is expected to announce its third-quarter results next month, and analysts predict a double-digit decline in the company’s bottom-line figure.

Barchart

Is Charles River Laboratories Stock Underperforming the Dow?

Charles River Laboratories underperformed the Dow recently, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Charles River Labs Plummets 14% On 'Bleaker' Expectations For 2024

Charles River Laboratories slashed its outlook for 2024 due to light pharma demand, and CRL stock plummeted in early trades.

Investors Business Daily

Charles River Laboratories Earnings Preview: What to Expect

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

Barchart

Wayne Brown's conversion on the road to Victoria St

Wayne Brown vowed to stop doing new roading projects until existing ones were finished, and to unclog the city centre's streets - but now finds himself enthusiastically backing a new period of upheaval for the key crossroad of Victoria St.

Newsroom.co.nz

Row erupts over 1,000 lab-test monkeys that may be killed or returned ‘to be trafficked again’

Conservationists demand urgent meeting with company summonsed to court by justice chiefs

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Charles River Tumbles As DOJ, PETA Zero In On Monkey Shipments

Charles River Laboratories announced a shortfall in monkey shipments on Wednesday that weighed on its 2023 outlook, and CRL stock toppled.

Newsroom.co.nz

Auckland: The shape of midtown to come

The City Rail Link is just one of many developments over the next few years that could stand to utterly transform Auckland’s CBD.

Newcastle Herald

'Just wanted a day off school': Knights prop's journey from a gala day to NRLW

The Knights prop had no interest in rugby league five years ago.

Benzinga

FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate

The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ:ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC:RLFTF) ACER-001 (sodium phenylbutyrate), for urea cycle disorders (UCDs). The CRL states: "[The FDA's] field investigator could not complete inspection of [Acer's third-party contract packaging manufacturer] because the facility was not ready…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Stocks to Avoid: 3 Companies That Recently Issued Profit Warnings

The persistent macroeconomic and geopolitical headwinds continue to keep the stock market under immense pressure. Amid the uncertainties surrounding the stock market, it could be wise to avoid shares of Charles River Laboratories International (CRL), Credit Suisse Group AG (CS), and The Scotts Miracle-Gro (SMG) as these hard-hit companies have…

StockNews.com

Does Charles River Laboratories International Deserve a Place in Your Portfolio?

The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.

Benzinga

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

Benzinga

As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate

The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc's (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval…

Benzinga

Charles River Buys Contract Vivarium Research Services Firm In $295M Deal

Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,

Benzinga

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc's (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due to chronic kidney disease (CKD). Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. The FDA issues a CRL to indicate that the review cycle for an application is complete…

Benzinga

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

The FDA has declined to approve AstraZeneca Plc's (NASDAQ:AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.